On 5 Jul 2022 the UK Intellectual Property Office granted Patent number GB2595299 to mAbsolve. Publication of the patent is expected on 3 Aug 2022. The patent claims cover a range of variants in the immunoglobulin Fc region which effectively eliminate binding to Fc gamma receptors and associated cellular activation, without adverse effects on manufacturability, … Read more
Scancell, a UK based company developing anti-glycan antibodies, have today announced an agreement with mAbsolve to license our STR technology for Fc silencing. Full details available in the press release below.
Fully silent antibodies as true negative controls for in vitro and cell-based effector function assays Antibody Analytics Ltd., a leading provider of antibody effector function characterisation and immunology research services, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides Antibody Analytics with … Read more
Our CSO, Ian Wilkinson, will be attending PEGS Boston in the week of 2-6th May. Our antibody silencing technology will be on display all week at poster 94.
Our CSO, Ian Wilkinson, will be presenting on the importance of attenuating effector functions in therapeutics antibodies as part of the Antibody Discovery & Development webinar series being run by The Antibody Society. The event will be held on 28th April and is free to attend. To attend please sign up here. In this webinar Ian … Read more
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides Absolute Antibody clients with easy license-free access to the new STR Fc silencing platform for antibody research and development, while ensuring … Read more
evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with mAbsolve Ltd for mAbsolve’s proprietary STR technology. Under the agreement, evitria will supply their global client base with antibodies bearing STR silencing modifications. These clients will then be able to evaluate the STR technology in their experiments … Read more
This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). It has been exciting to see our work go through the stringent peer-review process at PLOS ONE and we have continued to receive excellent feedback as word of our work spreads further. To this end we have … Read more
We are delighted to announce that our novel STR silencing technology has been recently published in the peer reviewed and open access journal PLoS ONE. This is available to download by clicking on the image below. We would like to thank all our partners that contributed to this work: Absolute Antibody, ProImmune, Antibody Analytics, Reading … Read more
The STR antibody technology developed by mAbsolve for truly silenced antibodies has been licensed to ONA Therapeutics for evaluation in their pipeline of therapeutic antibodies for advanced cancer. Dr. Valerie Vanhooren, CEO of ONA Therapeutics, said: We are delighted to be working with the highly experienced mAbsolve team. Having access to the novel Fc silencing … Read more